Galleri Test

What is the Galleri test?

Galleri is a multi-cancer early detection (MCED) blood test made by GRAIL. From a single blood draw, it looks for signals of more than 50 types of cancer — most of which, such as pancreatic, ovarian, liver, and esophageal cancer, have no routine screening test today. We currently have proven screening programs for only a handful of cancers (breast, colorectal, cervical, and lung in high-risk smokers); Galleri is designed to widen the net beyond those.

The test has been sold in the United States since 2021 as a laboratory-developed test — a pathway that does not require FDA approval — and in September 2026 it became the first test of its kind to reach an FDA advisory panel vote. It is the most-watched test in a new wave of blood-based cancer screening, but it is not the only one: hundreds of companies are developing similar multi-cancer blood tests.²

How does the Galleri test work?

When cells die — including cancer cells — they release small fragments of DNA into the bloodstream (cell-free DNA). Cancer cells leave a distinctive chemical fingerprint on that DNA through a process called methylation, which works like a set of on-off switches on genes. Galleri uses next-generation sequencing to scan the methylation patterns in your cell-free DNA for cancer-specific signals.

When a signal is found, the test also predicts where in the body the cancer signal most likely started (the cancer signal origin), which helps direct the follow-up imaging and workup. The sample itself is collected through a standard blood draw — there is no special preparation, and no fasting requirement is advertised.

Who can get the Galleri test?

Galleri is a prescription-only test for adults 50 and older. A doctor must order it — you cannot buy it over the counter or order it yourself online. The proposed use covers the age group in which cancer risk climbs steeply.

It is specifically not for people who already have symptoms. If you have unexplained weight loss, persistent pain, unusual bleeding, or a new lump, you need a diagnostic workup for those symptoms — Galleri is a screening test for apparently healthy people, and the proposed labeling says so explicitly. It is also not intended as a reassurance tool for young, healthy adults outside the indicated age range.

Galleri test cost and insurance

In the United States, the Galleri test costs $949 out of pocket, and most patients pay the full amount themselves.¹ That is because health insurers — including Medicare — do not cover the test without full FDA approval, which has not yet arrived.

The coverage picture may change. A law signed on February 3, 2026 allows Medicare, starting in 2028, to cover one FDA-approved multi-cancer screening test per year, if the Centers for Medicare & Medicaid Services (CMS) determines coverage is appropriate.³ That is a real shift: if Galleri wins FDA approval, the out-of-pocket math for Medicare beneficiaries could change quickly. Until then, do not pay for the test on the assumption Medicare will reimburse you — coverage only begins after approval, which had not happened as of late September 2026.

A few employers, including Salesforce, already offer the test as a workplace health benefit.⁴ Galleri is not marketed or widely available in India as of this writing; the test discussed here is the US prescription product.

How to get the Galleri test

The path is straightforward but runs entirely through a clinician:

1. Talk to your doctor. Ask whether Galleri makes sense given your age (50+), your personal and family cancer history, and whether you are current on the proven screenings (colonoscopy, mammogram, cervical screening, and lung CT if eligible).
2. Get the order. Your doctor writes the prescription or orders through an enrolled telehealth provider.
3. Give blood. A standard blood draw at a participating lab — no fasting or special preparation advertised.
4. Wait for results. The report goes to the ordering clinician, who explains what it means and what, if anything, comes next.

Before you test, ask three practical questions: what would a positive result trigger?, would the follow-up scans be covered by my insurance?, and am I current on the screenings already proven to save lives? A positive result starts a diagnostic process with real costs and real anxiety — it should never be a surprise.³

What the results mean

A positive result is the start of a process, not a diagnosis. Roughly half of the people with a positive result in the trials were eventually confirmed to have cancer — the other half went through scans, specialist visits, and sometimes biopsies before learning they were likely cancer-free. The test’s specificity was high (about 99.55% in the NHS-Galleri trial), which is why positives are worth chasing — but a positive is not a cancer diagnosis until the workup says so.³

Accuracy and limitations

Honesty first: Galleri misses many cancers, especially at early stages. In the two main large clinical trials, the test often did not detect cancers that were present — something that drew concern from opponents at the FDA panel meeting. The director of the National Cancer Institute’s Division of Cancer Prevention told the panel the data were too premature to prove the test would be of any clinical benefit, warning that broad rollout could do more harm by giving people a false sense of security.²

And the most important unknown remains unanswered: there is no proof yet that Galleri reduces cancer deaths. That question is being studied separately — the NCI’s Vanguard Study will enroll up to 24,000 people to help design a much larger randomized trial testing whether multi-cancer tests actually save lives. Longer-term data from the UK trial may also show whether the test meaningfully reduces late-stage diagnoses.³

FDA approval status

On September 23, 2026, the FDA’s Molecular and Clinical Genetics Panel (part of the Medical Devices Advisory Committee) reviewed GRAIL’s premarket approval application and voted:

• 10–0 that Galleri is reasonably safe
• 6–4 that it is reasonably effective — a split vote showing real expert doubt
• 7–2 (one abstention) that its benefits outweigh its risks for adults 50 and older

It was the first time a multi-cancer blood test reached this stage. But a panel vote is only a recommendation — the FDA is not bound by it and had not announced when it will make its final decision as of late September 2026 (one report put the expected decision in the first quarter of 2027).^1,4 Until the FDA decides, Galleri stays available only as a $949 prescription lab-developed test — and the Medicare coverage law only activates after approval.

Frequently Asked Questions

Pharmacist’s practical notes

Start with the question that matters most: are you current on the screenings already proven to save lives? A colonoscopy, mammogram, cervical screening, or lung CT for eligible smokers has decades of mortality evidence behind it; Galleri has none yet. The test is an addition to that list, never a trade for it. Anyone considering paying $949 out of pocket should first make sure the free-or-covered proven screenings are actually done — that is the single highest-value cancer-screening action available today.

Read the result the way the trials read it. “Cancer signal detected” means roughly a coin flip — about half of positives in the trials were eventually confirmed to have cancer — and the workup that follows is real: imaging, specialist referrals, sometimes a biopsy, and weeks of worry. That is manageable when you plan for it and distressing when you don’t, which is why the pre-test conversation about follow-up costs and insurance coverage is as important as the test itself. Do not let anyone order this test for you without that conversation.

Respect what a negative result is not. The test misses many cancers, especially early-stage disease, and the proposed labeling says a negative result does not rule out cancer. New symptoms — unexplained weight loss, persistent pain, unusual bleeding, a new lump — override any blood test and need prompt medical attention. A negative Galleri result should never be the reason you skip a scheduled mammogram or colonoscopy.

Finally, watch the calendar, not just the headlines. The September 2026 panel vote was a recommendation, not an approval; the FDA’s final decision is the event that changes everything, because the Medicare coverage law signed in February 2026 only activates after approval. If you are on the fence about paying $949 today, waiting for the FDA decision — and asking your Medicare plan afterward what you would owe — is a defensible choice. Whatever you decide, discuss it with your own doctor, who knows your personal and family cancer history.

References

1. Becker’s Hospital Review. FDA panel backs first multi-cancer blood test: what to know (Sept 24, 2026).
2. NPR. FDA advisory panel recommends a first: multi-cancer blood test (Sept 23, 2026).
3. Medscape. FDA Panel Votes on Multicancer Test, Highlights Data Gaps (Sept 2026).
4. MarketWatch via Morningstar. This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval (Sept 23, 2026).